NasdaqGS:BEAT

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

BioTelemetry, Inc., a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide.


Snowflake Analysis

Reasonable growth potential and fair value.


Similar Companies

Share Price & News

How has BioTelemetry's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BEAT has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-7.4%

BEAT

-3.0%

US Healthcare

2.3%

US Market


1 Year Return

-12.9%

BEAT

4.2%

US Healthcare

6.7%

US Market

Return vs Industry: BEAT underperformed the US Healthcare industry which returned 4.2% over the past year.

Return vs Market: BEAT underperformed the US Market which returned 6.7% over the past year.


Shareholder returns

BEATIndustryMarket
7 Day-7.4%-3.0%2.3%
30 Day-6.2%0.9%7.4%
90 Day-2.5%7.3%17.9%
1 Year-12.9%-12.9%5.6%4.2%9.0%6.7%
3 Year22.7%22.7%24.7%19.2%36.6%27.7%
5 Year263.2%263.2%33.2%24.0%64.2%46.1%

Price Volatility Vs. Market

How volatile is BioTelemetry's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is BioTelemetry undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: BEAT ($42.2) is trading below our estimate of fair value ($100.7)

Significantly Below Fair Value: BEAT is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: BEAT is poor value based on its PE Ratio (56.9x) compared to the US Healthcare industry average (22.5x).

PE vs Market: BEAT is poor value based on its PE Ratio (56.9x) compared to the US market (16.2x).


Price to Earnings Growth Ratio

PEG Ratio: BEAT is good value based on its PEG Ratio (0.9x)


Price to Book Ratio

PB vs Industry: BEAT is overvalued based on its PB Ratio (3.8x) compared to the US Healthcare industry average (2.7x).


Next Steps

Future Growth

How is BioTelemetry forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

62.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BEAT's forecast earnings growth (62% per year) is above the savings rate (2.2%).

Earnings vs Market: BEAT's earnings (62% per year) are forecast to grow faster than the US market (22.9% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: BEAT's revenue (14.9% per year) is forecast to grow faster than the US market (9.4% per year).

High Growth Revenue: BEAT's revenue (14.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BEAT's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has BioTelemetry performed over the past 5 years?

24.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BEAT has high quality earnings.

Growing Profit Margin: BEAT's current net profit margins (5.9%) are lower than last year (12.5%).


Past Earnings Growth Analysis

Earnings Trend: BEAT has become profitable over the past 5 years, growing earnings by 24.1% per year.

Accelerating Growth: BEAT's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: BEAT had negative earnings growth (-47.9%) over the past year, making it difficult to compare to the Healthcare industry average (10.1%).


Return on Equity

High ROE: BEAT's Return on Equity (6.7%) is considered low.


Next Steps

Financial Health

How is BioTelemetry's financial position?


Financial Position Analysis

Short Term Liabilities: BEAT's short term assets ($213.1M) exceed its short term liabilities ($49.1M).

Long Term Liabilities: BEAT's short term assets ($213.1M) do not cover its long term liabilities ($314.3M).


Debt to Equity History and Analysis

Debt Level: BEAT's debt to equity ratio (60.3%) is considered high.

Reducing Debt: BEAT's debt to equity ratio has increased from 37.5% to 60.3% over the past 5 years.

Debt Coverage: BEAT's debt is well covered by operating cash flow (27.6%).

Interest Coverage: BEAT's interest payments on its debt are well covered by EBIT (7x coverage).


Balance Sheet


Next Steps

Dividend

What is BioTelemetry current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BEAT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BEAT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BEAT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BEAT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BEAT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.3yrs

Average management tenure


CEO

Joe Capper (56yo)

10.08yrs

Tenure

US$4,133,155

Compensation

Mr. Joseph H. Capper, also known as Joe, has been the Chief Executive Officer and President at BioTelemetry, Inc. formerly known as CardioNet, Inc. since June 2010. Mr. Capper served as the Chief Executive ...


CEO Compensation Analysis

Compensation vs Market: Joe's total compensation ($USD4.13M) is about average for companies of similar size in the US market ($USD4.72M).

Compensation vs Earnings: Joe's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Joseph Capper
CEO, President & Director10.08yrsUS$4.13m0.32% $4.6m
Heather Getz
Executive VP10.5yrsUS$1.67m0.10% $1.5m
Fred Broadway
President of BioTel Heart2.5yrsUS$1.06m0.071% $1.0m
Daniel Wisniewski
Senior Vice President of Technical Operations9.58yrsUS$921.54k0.063% $910.4k
Peter Ferola
Consultant0.58yrUS$911.67kno data
Andrei Stoica
Chief Technology Officer0.25yrno datano data
Cody Cowper
Vice President of Legal & Corporate Secretaryno datano datano data
Amy Knapp
Vice president of Corporate Communicationsno datano datano data
Tim Raher
Senior Vice President of Human Resources3yrsno datano data
Peter Kowey
Medical Director and Chairman of Medical Advisory Board11.33yrsno datano data

6.3yrs

Average Tenure

51yo

Average Age

Experienced Management: BEAT's management team is seasoned and experienced (6.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Joseph Capper
CEO, President & Director10.08yrsUS$4.13m0.32% $4.6m
Peter Kowey
Medical Director and Chairman of Medical Advisory Board11.33yrsno datano data
Kirk Gorman
Independent Chairman8.75yrsUS$278.85k0.52% $7.5m
Rebecca Rimel
Independent Director11.17yrsUS$207.55k0.33% $4.8m
David Benditt
Member of Medical Advisory Boardno datano datano data
Joseph Frick
Independent Director6.75yrsUS$202.62k0.17% $2.4m
Robert Rubin
Independent Director13yrsUS$200.09k0.52% $7.6m
Arthur Moss
Member of Medical Advisory Board11.33yrsno datano data
Kenneth Ellenbogen
Member of Medical Advisory Board11.33yrsno datano data
Anthony Conti
Independent Director8.17yrsUS$205.05k0.30% $4.3m

11.2yrs

Average Tenure

69yo

Average Age

Experienced Board: BEAT's board of directors are seasoned and experienced ( 11.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

BioTelemetry, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BioTelemetry, Inc.
  • Ticker: BEAT
  • Exchange: NasdaqGS
  • Founded: 1994
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: US$1.441b
  • Shares outstanding: 34.14m
  • Website: https://www.gobio.com

Number of Employees


Location

  • BioTelemetry, Inc.
  • 1000 Cedar Hollow Road
  • Suite 102
  • Malvern
  • Pennsylvania
  • 19355
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
C25DB (Deutsche Boerse AG)YesCommon StockDEEURMar 2008
BEATNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMar 2008
0HNHLSE (London Stock Exchange)YesCommon StockGBUSDMar 2008

Biography

BioTelemetry, Inc., a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in Healthcare, Research, and Corporate and Other segments. The Healthcare segment focuses on the remote cardiac monitoring to identify arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, and non-loop event monitors. It also provides Holter and extended-wear Holter monitors, and INR monitoring services. It serves cardiologists, electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, such as cardiac monitoring, imaging, scientific consulting, and data management services for drug and medical device trials. Its centralized services comprise electrocardiogram, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, imaging, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The Corporate and Other segment focuses on the manufacture, engineering, development, and sale of non-invasive cardiac monitors and other population health management devices for healthcare companies, as well as contract manufacturing services under the BioTel Care and BioTel Alliance names. The company was founded in 1994 and is headquartered in Malvern, Pennsylvania. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/11 23:58
End of Day Share Price2020/07/10 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.